We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 22:29:19 |
From May 2019 to May 2024
By Carlo Martuscelli
Novartis AG (NVS, NOVN.EB) said Friday that the European Medicines Agency recommended Mayzent as a treatment for adult patients with secondary progressive multiple sclerosis.
The EMA's Committee for Medicinal Products for Human Use gave a positive opinion on the drug as a treatment for adult patients who show evidence of relapse or inflammatory activity, the Swiss drug maker said.
In most cases a recommendation by the CHMP leads to marketing approval from the European Commission.
Novartis said that the decision is based on positive results from the Phase 3 Expand trial which showed that Mayzent was able to slow the progress of SPMS in treated patients.
The U.S. approved the drug for relapsing forms of multiple sclerosis in March.
Novartis said that regulatory filings to secure approval for Mayzent were underway in Switzerland, Japan, Canada, and China.
Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu
(END) Dow Jones Newswires
November 15, 2019 07:06 ET (12:06 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
